Lab21 secures additional IP for Hepatitis C diagnostics
"Lab 21 is committed to providing advanced healthcare testing services and licensing Dr. Holland's technology will allow us to further our development in the area of HCV testing." said Berwyn Clarke, Chief Scientific Officer of Lab 21. He continued: "HCV is a virus that is likely to resemble HIV in that antiviral drug resistance will become a significant issue as and when new small molecule drugs are licensed. The acquisition of this technology is a powerful tool in support of our commitment to develop resistance genotyping assays that will allow optimal clinical management of HCV patients."
The details and terms of the agreement were not disclosed.
Other news from the department research and development
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.